PINNED
PINNED
Pharma Horizons: leading-edge formulation
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
List view / Grid view
Articles
European Pharmaceutical Review Issue 4 2019
This issue includes an investigation into the potential for continuous production lines in biopharma, information on new guidance released by China on their regulatory processes and an assessment of the FMD to improve the drug supply chain. Also within the issue are articles on nanomedicine development, monoclonal antibodies and pharmaceutical…
Cannabinoids in pharma series: the future prospects of cannabinoids
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this third piece, we discuss the future of the cannabinoid industry and how it will grow within the realm of pharmaceuticals.
Cannabinoids in pharma series: the challenges of working with cannabinoids
This series investigates cannabinoids and pharmaceutical interest with industry experts explaining the position of the ingredient. In this second piece, we discuss the challenges, legal implications and perceptions of cannabinoids.
Cannabinoids in pharma series: cannabinoids on the market today
This series investigates the growing interest from the pharmaceutical industry in cannabinoids. In this first piece, we hear from industry experts about the current situation of the ingredient on the pharmaceutical market.
The Nagoya Protocol: sharing the benefits of pharmaceutical products and protecting biodiversity
Researchers use the Earth’s biodiversity for pharmaceuticals, but this is under threat due to climate change and habitat destruction. The Nagoya Protocol aims to conserve these resources in a sustainable way.
Climate change: how pharma will profit from a warming planet
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
Surge in negative verifications of saleable returns could cost pharma industry billions
The pharmaceutical industry is set to face some major changes in the near future, to improve the quality of returned drugs and medications.
Top five generic drug makers
The global generic drugs market continues to grow. With increasing demand for more accessible medication, pharmaceutical companies are harnessing the benefits offered by generic drugs. Here are the top five generic drugs makers by revenue.
The impact of counterfeit drugs in south and south-east Asia
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
Digital design for pharmaceutical product and process development
New digital design and manufacturing techniques offer pharmaceutical manufacturers the possibility of a systems-based, digital approach to substantially streamline their design, development and manufacturing processes. The ADDoPT collaborative consortium has been working to explore how emerging process understanding and predictive models can be applied and embedded within industrial workflows to…
Raman spectroscopy of the amorphous phase from silicon to pharmaceutical drugs – a brief overview
Zafar Iqbal sheds light on how Raman spectroscopy is used to detect and understand the amorphous phase in a range of solids, providing examples of his own laboratory applications.
Do viability methods detect all viable organisms?
Many bacterial species have been found to exist in a viable but non-culturable state. Jeanne Moldenhauer discusses this phenomenon and makes suggestions as to why we don’t often see an increase in viable cells when using viability-based methods.
Assessing host cell protein contamination in biotechnological products
Purification of a drug from host cell protein contaminants can be challenging, with low-level contamination often remaining after purification. Vanda Dolabela de Magalhães shares discussions on the subject from six Brazilian companies working in the biotech field.
Capsosomes: the revolutionary enzyme carriers
Nature can offer inspiration for the synthesis of more effective drug delivery platforms. In this article, Marc Baiget Francesch discusses the potential of capsosomes as a novel, biocompatible, drug delivery system.
Manufacturing medical devices to ISO 13485:2016
Continuous innovation is key to the advancement of medical device technology. To allow for innovation, whilst also assuring safety and effectiveness, global standards are required. This article provides information for companies manufacturing medical devices on the benefits of holding ISO 13485 certification and how to get certified.
